A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphataemia

Trial Profile

A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphataemia

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Colestilan (Primary)
  • Indications Hyperphosphataemia
  • Focus Adverse reactions; Registrational
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 31 Mar 2014 New trial record
    • 21 Sep 2010
    • 05 Aug 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top